NCT04632199View on ClinicalTrials.gov

Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 12, 2021

Primary Completion Date

December 10, 2021

Study Completion Date

December 10, 2021

Conditions
Pancreatic Ductal AdenocarcinomaColorectal Cancer
Interventions
DRUG

111In-IPN01087 Low dose

Administered once via slow intravenous injection.

DRUG

111In-IPN01087 High dose

Administered once via slow intravenous injection.

Trial Locations (5)

1000

Institut Jules Bordet, Brussels

3000

UZ Leuven, Leuven

44087

CHU de Nantes - Hôpital Hôtel Dieu, Nantes

54511

CHRU de Nancy - Hôpital de Brabois, Nancy

69008

Centre Léon Bérard, Léon

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT04632199 - Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer. | Biotech Hunter | Biotech Hunter